MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Benzocaine

CAS No. : 94-09-7

MCE 站：Benzocaine

产品活性：Benzocaine 作用电压门控Na⁺通道的共同受体，其在 +30 mV 下测得的 IC₅₀ 值为0.8 mM。

研究领域：Membrane Transporter/Ion Channel

作用靶点：Sodium Channel

In Vitro: Benzocaine blocks μ1 wild-type Na⁺ currents in a dose-dependent Manner. The Benzocaine concentration that inhibits 50% of Na⁺ currents (IC₅₀) is estimated to be about 0.8 mM when a test potential of +30 mV is applied. The slope of the h∞ curve is also significantly reduced by benzocaine (from 6.6 to 9.9 mV). Mutation of μ1-N1584A also significantly increases the potency of Benzocaine. At 1 mM, Benzocaine blocks about 55% of wild-type Na⁺ current but about 95% of μ1-N1584A mutant current. Benzocaine also appears to bind more strongly to its LA receptor in the N1584A mutant than in the wild type. The inhibition of Ca²⁺ uptake occurres at lower Benzocaine concentration (IC₅₀=40.3±1.2mM) than that affecting the enzymatic activity.

In Vivo: Benzocaine is topically applied to the following species: dogs, domestic shorthair cats, Long-Evans rats, Sprague-Dawley rats, ferrets, rhesus monkeys, cynomolgus monkeys, owl monkeys, New Zealand White rabbits, miniature pigs, ICR mice, C3H mice, and C57BL/10SnJ mice. All animals, except mice and rats, receive a 2-second spray to the mucous membranes of the nasopharynx for an estimated dose of 56 mg. A 2-second spray to rodents' oral mucous membranes delivers too great a volume of fluid for these animals. The study is repeated in dogs several months later to confirm low response. Response to Benzocaine spray is observed in most animals tested, with response peaking between 15 and 30 minutes after dosing.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Membrane Transporter/Ion Channel Compound Library  |  FDA-Approved Drug Library  |  Fragment Library  |  Drug Repurposing Compound Library  |  NMPA-Approved Drug Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  EIPA  |  Amiloride hydrochloride  |  Monensin sodium salt  |  Carbamazepine  |  5-(N,N-Hexamethylene)-amiloride  |  Riluzole  |  20(S)-Ginsenoside Rg3  |  Lidocaine  |  Amitriptyline hydrochloride  |  Cariporide  |  Lamotrigine  |  Ranolazine dihydrochloride  |  Flecainide acetate  |  Phenytoin  |  Zonisamide  |  Veratridine  |  Oxcarbazepine  |  A-803467  |  Triamterene  |  Flunarizine dihydrochloride  |  Vinpocetine  |  QX-314 chloride  |  Dronedarone  |  Propafe hydrochloride  |  Mexiletine hydrochloride  |  Topiramate

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。